BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11361899)

  • 1. Liposomal amphotericin B found safe and effective.
    AIDS Patient Care STDS; 1998 Jan; 12(1):69. PubMed ID: 11361899
    [No Abstract]   [Full Text] [Related]  

  • 2. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D
    Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating disseminated fusariosis: amphotericin B, voriconazole or both?
    Ho DY; Lee JD; Rosso F; Montoya JG
    Mycoses; 2007 May; 50(3):227-31. PubMed ID: 17472622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AmBisome today: expanding the perspectives on liposomal amphotericin B.
    Richardson M
    Acta Biomed; 2006; 77 Suppl 2():3-4. PubMed ID: 16918058
    [No Abstract]   [Full Text] [Related]  

  • 5. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations.
    Winston DJ; Schiller GJ
    Clin Infect Dis; 2000 Jan; 30(1):236-7. PubMed ID: 10619780
    [No Abstract]   [Full Text] [Related]  

  • 6. Infection due to non-Aspergillus fungi in immunocompromised patients receiving itraconazole.
    Myoken Y; Sugata T; Mikami Y
    Clin Infect Dis; 2002 Aug; 35(4):494-5; author reply 495. PubMed ID: 12145737
    [No Abstract]   [Full Text] [Related]  

  • 7. Experience with liposomal amphotericin B at the Hematology-Oncology Department Children's Hospital Salata Medical School, University of Zagreb.
    Konja J; Glavas B; Anicić M
    Acta Biomed; 2006; 77 Suppl 2():14-6. PubMed ID: 16918061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient.
    Consigny S; Dhedin N; Datry A; Choquet S; Leblond V; Chosidow O
    Clin Infect Dis; 2003 Jul; 37(2):311-3. PubMed ID: 12856225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of liposomal amphotericin B in bone marrow transplant.
    Sastry PS; Parikh PM; Kulkarni PS; Bhagwat R; Gadade H
    J Postgrad Med; 2005; 51 Suppl 1():S49-52. PubMed ID: 16519256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A perspective on liposomal amphotericin B (AmBisome).
    Richardson M; de Pauw B
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():1-4. PubMed ID: 18430125
    [No Abstract]   [Full Text] [Related]  

  • 11. Disseminated Penicillium marneffei infection in a renal-transplant recipient successfully treated with liposomal amphotericin B.
    Wang JL; Hung CC; Chang SC; Chueh SC; La MK
    Transplantation; 2003 Oct; 76(7):1136-7. PubMed ID: 14557769
    [No Abstract]   [Full Text] [Related]  

  • 12. Liposome battle for antifungal market shifts into high gear.
    Marks S
    J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):46-7. PubMed ID: 11363518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusarium verticillioides abscess of the nasal septum in an immunosuppressed child: case report and identification of the morphologically atypical fungal strain.
    Dornbusch HJ; Buzina W; Summerbell RC; Lass-Flörl C; Lackner H; Schwinger W; Sovinz P; Urban C
    J Clin Microbiol; 2005 Apr; 43(4):1998-2001. PubMed ID: 15815043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of invasive fungal sinusitis with liposomal amphotericin B: a report of four cases.
    Sungkanuparph S; Sathapatayavongs B; Kunachak S; Luxameechanporn T; Cheewaruangroj W
    J Med Assoc Thai; 2001 Apr; 84(4):593-601. PubMed ID: 11460976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
    Cordonnier C; Bresnik M; Ebrahimi R
    Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
    Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality rates in comparative trials of formulations of amphotericin B.
    Frothingham R
    Clin Infect Dis; 2001 Aug; 33(4):582-3. PubMed ID: 11462201
    [No Abstract]   [Full Text] [Related]  

  • 18. Scedosporium infection in immunocompromised patients: successful use of liposomal amphotericin B and itraconazole.
    Barbaric D; Shaw PJ
    Med Pediatr Oncol; 2001 Aug; 37(2):122-5. PubMed ID: 11496350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
    Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
    Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Amphotericin B: the end of an era].
    Oude Lashof AM; Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1665-8. PubMed ID: 15453116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.